The present invention relates to a method for screening pore-forming membrane proteins, membrane transporters and molecular switches. The invention also relates to a kit for carrying out the method.

The present invention relates to a method for screening pore-forming membrane proteins, membrane transporters and molecular switches. The invention also relates to a kit for carrying out the method.

Methods for selecting polypeptides or proteins having one or more desired properties from a library of sequences expressed in eukaryotic cells, including: encapsulating the cells by photopolymerization; solubilizing the encapsulated cells to produce semipermeable microcapsules; optionally contacting the cells and/or the microcapsules with one or more agents to facilitate detection of activity or function of polypeptides or proteins of interest; and selecting polypeptides or proteins of interest having one or more desired properties. Also provided are methods for encapsulating eukaryotic cells for use in the selection of polypeptides and proteins as described above.

The present disclosure describes technologies that permit sensitive detection of nucleic acids of interest (i.e., nucleic acids whose nucleotide sequence is or includes a target sequence). Among other things the disclosure provides a system comprising: a plurality of nucleic acid molecules having different nucleotide sequences; a set of ligation oligonucleotides, comprising: a first ligation oligonucleotide whose nucleotide sequence includes a templating element and a first target hybridization element; and a second ligation oligonucleotide whose nucleotide sequence includes a second target hybridization element and optionally a second templating element; wherein the target hybridization elements bind to different portions of a common target site, to form a gapped nucleic acid strand susceptible to ligation with a ligase to generate a ligated strand that is amenable to lateral flow assessment.

The present invention provides a process and method for repurposing existing compounds by leveraging genomic, phenotypic and pharmacological data to cure disease. Applying advanced mathematical analytics using massively interconnected computing capabilities to identify target rich sets of existing compounds available for animal testing at the earliest stage in the process collapses cycle time of development, dramatically reducing costs. Target rich sets obtained through this invention produce compounds or compositions which each have a demonstrated ability to modulate disease or an associated phenotypic expression. By rendering the mechanism of action irrelevant, this invention collapses the time and cost to discovery of an efficacious drug from decades to days and from $Billions to $Millions.

The present invention provides a process and method for repurposing existing compounds by leveraging genomic, phenotypic and pharmacological data to cure disease. Applying advanced mathematical analytics using massively interconnected computing capabilities to identify target rich sets of existing compounds available for animal testing at the earliest stage in the process collapses cycle time of development, dramatically reducing costs. Target rich sets obtained through this invention produce compounds or compositions which each have a demonstrated ability to modulate disease or an associated phenotypic expression. By rendering the mechanism of action irrelevant, this invention collapses the time and cost to discovery of an efficacious drug from decades to days and from $Billions to $Millions.

The invention provides methods, devices, compositions and kits for diagnosing or predicting transplant status or outcome in a subject who has received a transplant.

The invention describes a method for the synthesis of compounds comprising the steps of: (a) compartmentalising two or more sets of primary compounds into microcapsules; such that a proportion of the microcapsules contains two or more compounds; and (b) forming secondary compounds in the microcapsules by chemical reactions between primary compounds from different sets; wherein one or both of steps (a) and (b) is performed under microfluidic control; preferably electronic microfluidic control, The invention further allows for the identification of compounds which bind to a target component of a biochemical system or modulate the activity of the target, and which is co-compartmentalised into the microcapsules.

A method of detecting and quantifying various enzymatic activities using a constructed artificial genetic circuit GESS (genetic enzyme screening system) for sensing phenolic compounds and a method of screening a trace of activities of target enzymes from a metagenome using the artificial genetic circuit, thereby securing target enzyme genes. When the method for screening and quantifying target enzymatic activity is used, useful genes can be screened from various genetic communities, including environmental or metagenomic libraries, at a single cell level in high throughput (million/day). Further, the sensitivity of the genetic circuit to phenol derivatives and the expression thereof can be controlled, and thus the genetic circuit can rapidly sense and quantify various enzymatic activities. Thus, the method can be advantageously used in the protein engineering technology for enzyme modification. Particularly, it can quantitatively investigate enzymatic activity, and thus can be applied to molecular evolution technology.

This invention provides methods and kits for diagnosing, ascertaining the clinical course of minimal residual disease associated with acute lymphoblastic leukemia (ALL). Specifically the invention provides methods and kits useful in the diagnosis and determination of clinical parameters associated with diseases associated with ALL based on patterns of surface marker expression unique to ALL.